Stellar Biotechnologies (NASDAQ:SBOT) Releases Earnings Results, Misses

Stellar Biotechnologies (NASDAQ:SBOT) issued its quarterly earnings data on Tuesday, February 5th. The biotechnology company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.03), Bloomberg Earnings reports. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.06 million. Stellar Biotechnologies had a negative return on equity of 52.71% and a negative net margin of 2,018.40%.

Shares of NASDAQ:SBOT remained flat at $$1.13 during midday trading on Wednesday. The stock had a trading volume of 54,765 shares, compared to its average volume of 271,793. Stellar Biotechnologies has a twelve month low of $0.75 and a twelve month high of $7.63. The stock has a market capitalization of $5.86 million, a P/E ratio of -0.64 and a beta of 1.11.

Separately, ValuEngine raised Stellar Biotechnologies from a “hold” rating to a “buy” rating in a research report on Thursday, November 1st.

COPYRIGHT VIOLATION NOTICE: “Stellar Biotechnologies (NASDAQ:SBOT) Releases Earnings Results, Misses Estimates By $0.03 EPS” was posted by Fairfield Current and is the property of of Fairfield Current. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The original version of this news story can be accessed at

About Stellar Biotechnologies

Stellar Biotechnologies, Inc, a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market.

Read More: Swap

Earnings History for Stellar Biotechnologies (NASDAQ:SBOT)

Receive News & Ratings for Stellar Biotechnologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Stellar Biotechnologies and related companies with’s FREE daily email newsletter.